Online inquiry

IVTScrip™ mRNA-Anti-C1S, BIVV009(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4312MR)

This product GTTS-WQ4312MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets C1S gene. The antibody can be applied in Cold agglutinin disease (CAD) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_001346850.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 716
UniProt ID P09871
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-C1S, BIVV009(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ4312MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6030MR IVTScrip™ mRNA-Anti-IL12B, CNTO 1275(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CNTO 1275
GTTS-WQ6048MR IVTScrip™ mRNA-Anti-IL6, CNTO 136(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CNTO 136
GTTS-WQ9203MR IVTScrip™ mRNA-Anti-MS4A1, IMMU-106(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IMMU-106
GTTS-WQ13474MR IVTScrip™ mRNA-Anti-ERBB2&TNFRSF9, PRS-343(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PRS-343
GTTS-WQ11192MR IVTScrip™ mRNA-Anti-TNFRSF4, MEDI0562(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MEDI0562
GTTS-WQ2463MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7, AMG 181(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 181
GTTS-WQ14208MR IVTScrip™ mRNA-Anti-IL17A, RG4934(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA RG4934
GTTS-WQ4025MR IVTScrip™ mRNA-Anti-IL23A, BI 655066(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BI 655066
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW